Business Context and Reporting Period
This Form 8-K filing by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp. in metadata) covers the event date of January 23, 2018. The report addresses regulatory compliance status regarding the company's listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and listing status events.
Material Changes
- Regulatory Compliance: The Company received written notice from the Nasdaq Stock Market, LLC confirming it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Stock Structure: This compliance follows the implementation of a one-for-ten reverse split of the Company's common stock, which became effective on January 8, 2018.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the prior listing deficiency. The primary risk addressed was the potential delisting due to low bid price, which has been resolved.
Investor Verification Checklist
- Verify the effective date of the one-for-ten reverse split (January 8, 2018) and its impact on share count and price.
- Confirm the current trading status of the stock on The Nasdaq Capital Market.
- Review the prior Form 8-K filed on January 5, 2018, for detailed information regarding the reverse split mechanics.